文献速递胸部肿瘤

局部晚期非小细胞肺癌患者中期PET/CT自适应放疗联合同步化疗的效果:一项2期临床试验

Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
PubMed 文献 · JAMA Oncol · 2017-01-01

这项2期临床试验在2个学术医疗中心纳入42例不可手术或不可切除的II至III期非小细胞肺癌患者,个体化适形放疗至固定放射性肺损伤风险,并根据中期FDG-PET自适应推量至中位83 Gy/30次,同步每周卡铂+紫杉醇后3周期巩固。2年野内和整体局部区域肿瘤控制率分别为82%和62%,中位总生存25个月,2年和5年总生存率分别为52%和30%。

要点

  • 42例局部晚期NSCLC患者接受中期FDG-PET自适应放疗推量,中位剂量83 Gy/30次。
  • 2年野内局部控制率82%,整体局部区域控制率62%,中位总生存25个月。
  • 2年和5年总生存率分别为52%和30%,RTOG 1106随机试验正在验证。

核心结论

  • 根据中期PET检测的FDG高摄取肿瘤进行自适应放疗推量,获得了有利的局部区域肿瘤控制。
  • RTOG 1106试验是一项正在进行的临床试验,旨在以随机方式验证这一发现。

研究设计与样本

  • 一项在2个学术医疗中心开展的2期临床试验,纳入42例不可手术或不可切除的II至III期NSCLC患者,入组时间为2008年11月至2012年5月。
  • 适形放疗个体化至固定的大于2级放射性肺损伤风险,并根据中期FDG-PET定义的残留肿瘤自适应推量至总剂量最高86 Gy/30次每日分割。
  • 医学上适合的患者接受同步每周卡铂加紫杉醇,随后3周期巩固治疗。
  • 主要终点为局部肿瘤控制,试验设计预期2年控制率较既往临床试验经验中63至69 Gy的34%提高20%。

主要发现

  • 试验达到42例的入组目标:中位年龄63岁(范围45-83岁);男性28例(67%);吸烟者或既往吸烟者39例(93%);III期38例(90%)。
  • 中位肿瘤照射剂量为83 Gy(范围63-86 Gy),30次每日分割。
  • 存活患者中位随访47个月。
  • 2年野内和整体局部区域肿瘤控制率(即包括孤立淋巴结失败)分别为82%(95%CI,62%-92%)和62%(95%CI,43%-77%)。
  • 中位总生存为25个月(95%CI,12-32个月);2年和5年总生存率分别为52%(95%CI,36%-66%)和30%(95%CI,16%-45%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Our previous studies demonstrated that tumors significantly decrease in size and metabolic activity after delivery of 45 Gy of fractionated radiatiotherapy (RT), and that metabolic shrinkage is greater than anatomic shrinkage. This study aimed to determine whether 18F-fludeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) acquired during the course of treatment provides an opportunity to deliver higher-dose radiation to the more aggressive areas of the tumor to improve local tumor control without increasing RT-induced lung toxicity (RILT), and possibly improve survival. OBJECTIVE: To determine whether adaptive RT can target high-dose radiation to the FDG-avid tumor on midtreatment FDG-PET to improve local tumor control of locally advanced non-small-cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS: A phase 2 clinical trial conducted at 2 academic medical centers with 42 patients who had inoperable or unresectable stage II to stage III NSCLC enrolled from November 2008, to May 2012. Patients with poor performance, more than 10% weight loss, poor lung function, and/or oxygen dependence were included, providing that the patients could tolerate the procedures of PET scanning and RT. INTERVENTION: Conformal RT was individualized to a fixed risk of RILT (grade >2) and adaptively escalated to the residual tumor defined on midtreatment FDG-PET up to a total dose of 86 Gy in 30 daily fractions. Medically fit patients received concurrent weekly carboplatin plus paclitaxel followed by 3 cycles of consolidation. MAIN OUTCOMES AND MEASURES: The primary end point was local tumor control. The trial was designed to achieve a 20% improvement in 2-year control from 34% of our prior clinical trial experience with 63 to 69 Gy in a similar patient population. RESULTS: The trial reached its accrual goal of 42 patients: median age, 63 years (range, 45-83 years); male, 28 (67%); smoker or former smoker, 39 (93%); stage III, 38 (90%). Median tumor dose delivered was 83 Gy (range, 63-86 Gy) in 30 daily fractions. Median follow-up for surviving patients was 47 months. The 2-year rates of infield and overall local regional tumor controls (ie, including isolated nodal failure) were 82% (95% CI, 62%-92%) and 62% (95% CI, 43%-77%), respectively. Median overall survival was 25 months (95% CI, 12-32 months). The 2-year and 5-year overall survival rates were 52% (95% CI, 36%-66%) and 30% (95% CI, 16%-45%), respectively. CONCLUSIONS AND RELEVANCE: Adapting RT-escalated radiation dose to the FDG-avid tumor detected by midtreatment PET provided a favorable local-regional tumor control. The RTOG 1106 trial is an ongoing clinical trial to validate this finding in a randomized fashion. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01190527.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Kong FM, Ten Haken RK, Schipper M, et al. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2017. PMID: 28570742. doi:10.1001/jamaoncol.2017.0982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。